Company Overview and News

 
Strategic Elements waits on decision for Pilbara ballot

2018-09-19 proactiveinvestors.com.au
Strategic Elements Ltd (ASX:SOR) is waiting on a decision to be made as part of a ballot process for two areas prospective for conglomerate-hosted gold in the East Pilbara region.
SOR NSRPF NVO

 
Strategic Elements looks to extend research program with CSIRO

2018-08-20 proactiveinvestors.com.au
Strategic Elements Ltd (ASX:SOR) continues to work with the CSIRO regarding the development of its Nanocube Memory Ink technology.
SOR

 
Strategic Elements advancing dual focus on technology and gold exploration

2018-08-19 proactiveinvestors.com.au
Strategic Elements Ltd (ASX:SOR) is a unique ASX-listed company given its focus on both new printable memory technology and conglomerate-hosted gold exploration in the Pilbara.
SOR NSRPF NVO

 
Strategic Elements throws hat in ring for conglomerate-hosted gold tenements

2018-08-16 proactiveinvestors.com.au
Strategic Elements Ltd (ASX:SOR) has entered into formal ballot processes to secure two areas prospective for conglomerate-hosted gold near Marble Bar in East Pilbara, Western Australia.
SOR NSRPF NVO

 
Strategic Elements completes fieldwork at three Pilbara gold projects

2018-08-14 proactiveinvestors.com.au
Strategic Elements Ltd (ASX:SOR) recently completed initial fieldwork targeting conglomerate-hosted and alluvial gold at three projects in the West Pilbara area of Western Australia.
SOR

 
Strategic Elements continues exploration push at Pilbara gold projects

2018-06-15 proactiveinvestors.com.au
Strategic Elements Ltd (ASX:SOR) has been granted seven of its 100% owned Pilbara gold projects with two more also pending.
SOR

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:SOR / STRATEGIC ELEMENTS LIMITED on message board site Silicon Investor.

Clown-Free Zone... sorry, no clowns allowed Clown-Free Zone... sorry, no clowns allowed Clown-Free Zone... sorry, no clowns allowed Sorrento Therapeutics Inc Sorrento Therapeutics Inc Sorrento Therapeutics Inc
Indications -- Psoriasis/Chronic Inflammation Indications -- Psoriasis/Chronic Inflammation Indications -- Psoriasis/Chronic Inflammation SORL - SORL Auto Parts SORL - SORL Auto Parts SORL - SORL Auto Parts
Piffer OT - And Other Assorted Nuts Piffer OT - And Other Assorted Nuts Piffer OT - And Other Assorted Nuts Wynn Resorts Wynn Resorts Wynn Resorts
ILLEGAL ALIEN NATION---THE SOROS/OBAMA USA ILLEGAL ALIEN NATION---THE SOROS/OBAMA USA ILLEGAL ALIEN NATION---THE SOROS/OBAMA USA SSS -- SOROSu0027 STORY STOCKS SSS -- SOROSu0027 STORY STOCKS SSS -- SOROSu0027 STORY STOCKS
The Beginning of Sorrows: World War III on Christmas and Eas The Beginning of Sorrows: World War III on Christmas and Eas The Beginning of Sorrows: World War III on Christmas and Eas Indications -- neurodevelopmental disorders Indications -- neurodevelopmental disorders Indications -- neurodevelopmental disorders